A powerful shift is underway in the global healthcare market as low-cost generic versions of leading weight-loss drugs begin to challenge giants like Ozempic and Wegovy, promising wider access—but also raising safety concerns.
Cheaper alternatives drive mass adoption
The expiry of semaglutide patents in key markets has opened the door for a wave of generic manufacturers, offering treatments at up to 70% lower prices than branded options.
Where patients once paid around $200 per month, newer alternatives are entering the market at just $13 to $44, making these therapies far more accessible for managing Type 2 diabetes and obesity.
This dramatic price drop is expected to accelerate demand, turning weight-loss medication into a mainstream healthcare solution rather than a premium offering.
India emerges as a key global player
India is quickly becoming a central hub for the production and export of generic semaglutide, with more than 40 companies preparing to supply international markets including Latin America, Canada, and Turkey.
According to experts at Burjeel Holdings, the availability of affordable options could significantly expand treatment access, particularly among patients who previously faced financial barriers.
Doctors in UAE highlight safety risks
While the benefits are clear, healthcare professionals are raising red flags over misuse and lack of supervision.
At NMC Royal Hospital, specialists report growing concerns about complications linked to improper use, including pancreatitis and other metabolic issues.
Despite stricter regulations requiring prescriptions since 2023, some patients continue to obtain these medications outside regulated systems.
Doctors stress that safe use depends on:
- Medical prescription and specialist monitoring
- Purchasing only through licensed healthcare providers
- Regular follow-ups to manage risks and side effects
- Pharma leaders respond with innovation push
As generics gain ground, leading companies like Novo Nordisk and Eli Lilly are stepping up innovation to maintain their dominance.
Novo Nordisk’s advanced high-dose Wegovy injection has delivered over 20% average weight loss, reinforcing the effectiveness of branded treatments even amid rising competition.
With the global obesity drug market projected to exceed $100 billion by 2030, the battle between affordability and innovation is intensifying.
A defining shift in obesity care
The arrival of generic semaglutide marks a turning point in the fight against obesity—making treatment more accessible than ever before.
However, experts warn that this progress must be balanced with strict medical oversight to avoid serious health risks.
As competition heats up, the focus will remain on delivering safe, effective, and affordable care in an increasingly crowded market.
